Oxford Biomedica Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Oxford, England, UK
Oxford Biomedica is a global contract development and manufacturing organisation specializing in cell and gene therapy viral vector production for pharmaceutical and biotechnology clients worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@oxb.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1995
Headquarters
Oxford, England, UK
Revenue
$100M-$250M
FUNDING Stage
Public
Website
Key Executives
Frank Mathias (Chief Executive Officer), Lucinda Crabtree (Chief Financial Officer), Kyriacos Mitrophanous (Chief Innovation Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Oxford Biomedica?
Oxford Biomedica uses the firstinitiallast format, so Jane Smith would be jsmith@oxb.com.
What viral vector platforms does Oxford Biomedica offer to cell and gene therapy clients?
Oxford Biomedica offers three proprietary viral vector platforms: LentiVector for lentiviral vectors, inAAVate for AAV, and AdenoVate for adenoviral vectors, supporting clients from pre-clinical development through commercial manufacturing.
Where are Oxford Biomedica's manufacturing sites located?
Oxford Biomedica operates manufacturing sites in Oxford and the UK, Lyon and Strasbourg in France, Bedford Massachusetts, and a commercial-scale viral vector facility in Durham, North Carolina, which became operational in 2026.
How can I find the right Oxford Biomedica contact for a CDMO partnership inquiry?
You can use Clay to look up Oxford Biomedica contacts by role or location and verify their email using the firstinitiallast@oxb.com format, making it straightforward to reach the right business development or scientific contact for your program.
Who leads Oxford Biomedica as Chief Executive Officer in 2026?
Frank Mathias serves as Chief Executive Officer of Oxford Biomedica. He joined the board in March 2023 and previously led both Rentschler Biopharma SE and Medigene AG.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating